Novavax Inc. may have failed to make the list of coronavirus vaccine developers picked for President Trump's Operation Warp Speed initiative but it is getting up to $60m from the US government for its investigational COVID-19 candidate.
Coronavirus Update: After 'Warp Speed' Snub, Novavax Awarded US Military Vaccine Deal
Plus: Inovio Launches First South Korea Vaccine Study
Progress for two US-based companies in the race to develop a COVID-19 vaccine.
More from Clinical Trials
More from R&D
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.